Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001640334-25-002275
Filing Date
2025-12-10
Accepted
2025-12-10 10:56:16
Documents
21
Period of Report
2026-01-27

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A lxrp_def14a.htm   iXBRL DEF 14A 486272
7 lxrp_def14aimg20.jpg GRAPHIC 187890
8 lxrp_def14aimg15.jpg GRAPHIC 6078
9 lxrp_def14aimg16.jpg GRAPHIC 1376
10 lxrp_def14aimg17.jpg GRAPHIC 1441
11 lxrp_def14aimg18.jpg GRAPHIC 1371
12 lxrp_def14aimg19.jpg GRAPHIC 10531
  Complete submission text file 0001640334-25-002275.txt   1371460

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lxrp-20250831.xsd EX-101.SCH 4379
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lxrp-20250831_lab.xml EX-101.LAB 12503
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE lxrp-20250831_cal.xml EX-101.CAL 1249
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lxrp-20250831_pre.xml EX-101.PRE 8228
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lxrp-20250831_def.xml EX-101.DEF 2449
23 EXTRACTED XBRL INSTANCE DOCUMENT lxrp_def14a_htm.xml XML 94684
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Filer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
Type: DEF 14A | Act: 34 | File No.: 001-39874 | Film No.: 251561149
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)